LEUKOPENIA MEDICINE is the latest in a string of new medicines to be developed by a British company.
The new drug, LYTRAZON, is the first to be licensed in the United Kingdom and the first approved for use in the UK.LYTREZON works by targeting the protein of the immune system and targeting the immune cells that cause myalgias, or chronic fatigue syndrome, the UK’s Daily Mail reports.
The drug targets the B cells that trigger inflammation and can potentially prevent myalgitis from progressing.
In a recent clinical trial, the drug was given to people with moderate-to-severe myalgics.
In one trial, they experienced mild to moderate fatigue and improved symptoms and function compared to people who didn’t take the drug.
The people who took the drug experienced an average decrease in symptoms of 1.5 to 2 days, according to researchers.
Dr. Simon Jones, from the Wellcome Trust, said the drug’s results have been “a major milestone in the treatment of myalgia and other inflammatory conditions.”
“In people with chronic fatigue, the B cell response is triggered by the inflammatory process in the body and the body’s ability to produce cytokines is inhibited,” he said.
“If we can target the B-cell response to this inflammatory process, then we can increase the body temperature and the level of inflammation.”
This is very exciting for people with myalgies, for their doctors and their patients, because we now have an idea of how to improve this inflammatory response.
We are working towards this target now.
“The drug, which is being developed by Oxford University, is being licensed in England and Wales, and is being tested in patients with chronic myalgial syndromes, including arthritis, osteoarthritis and psoriasis.
According to the drug manufacturer, the drugs have a lower risk of side effects than standard treatments.
The drug works by activating a protein that produces a hormone that helps the immune response.
The hormone activates the immune cell that triggers inflammation.
Dr Jones said LYTRAZON could be used in the clinic as a treatment for inflammatory arthritis, and to treat a variety of other inflammatory disorders, including chronic fatigue and rheumatoid arthritis.”
There are a range of different autoimmune conditions where the immune activity of the B lymphocytes in the immune responses of the myeloid cells is blocked,” he explained.”
So we could potentially use this drug to improve those autoimmune conditions.
“Dr Jones added that the drug could be useful in patients who have chronic fatigue as well, or in patients in the elderly who have difficulty regulating the immune function of the body.
The research was supported by the Wellbeing Institute at Oxford University.